TSHA — Taysha Gene Therapies, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1806310 ·
Last close
$6.34
Market Cap
$1.82B
52W High
$7.30
52W Low
$4.36
ADV30
3,430,687
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -43,486,000 | -42,410,000 | 300,351,000 | 276,576,000 | 88,407,000 |
| Dec 2025 | 5,485,000 | — | -28,300,000 | -27,851,000 | 343,320,000 | 319,767,000 | 96,382,000 |
| Sep 2025 | 0 | — | -34,024,000 | -32,733,000 | 316,554,000 | 297,344,000 | 97,565,000 |
| Jun 2025 | 1,986,000 | — | -26,753,000 | -26,882,000 | 333,331,000 | 312,761,000 | 84,604,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-93,090,000
Investing CF
$-604,000
Financing CF
$274,589,000
CapEx
$-738,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.36
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-711,300,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-108,932,000
Pretax Income TTM
$-108,995,000
Interest Exp TTM
$63,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,471,000
EBITDA
$-131,406,000
Free Cash Flow
$-73,448,000
Enterprise Value
$1,679,936,896
Total Cash
$276,576,000
Total Debt
$68,551,000
Shares Out
287,361,020
Trailing EPS
$-0.38
Book Value
$0.74
ROE
-97.3%
ROA
-37.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,773,000 | -110,498,000 | -108,995,000 | 343,320,000 | 96,382,000 | — | -93,090,000 |
| Dec 2024 | 8,333,000 | -86,621,000 | -89,298,000 | 160,364,000 | 88,839,000 | — | -81,225,000 |
| Dec 2023 | 15,451,000 | -71,374,000 | -111,566,000 | 172,731,000 | 97,794,000 | — | -73,018,000 |
| Dec 2022 | 2,502,000 | -126,027,000 | -166,014,000 | 126,276,000 | 125,327,000 | — | -88,390,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.43
Max Pain — expiry 2026-07-17
max pain strike: $6.00 · spot: $6.34 · call oi: 17,337 · put oi: 1,113
Expected Move to 2026-07-17:
±$0.73
(11.44%) —
implied range
$5.62 –
$7.07
· ATM straddle on $6.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.87B | $3.56 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $1.78B | $38.03 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $1.89B | $4.23 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.95B | $23.04 | — |
| MAZE | Maze Therapeutics, Inc. | $1.69B | $30.57 | — |
News headlines (Yahoo Finance, 1h cache)
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
2026-06-25 20:01 · Yahoo
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
2026-06-25 02:33 · Yahoo
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-06-24 20:01 · Yahoo
Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)
2026-06-22 12:56 · Yahoo
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
2026-06-22 12:00 · Yahoo
Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery
2026-06-13 12:12 · Yahoo
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?
2026-06-11 18:00 · Yahoo
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-06-05 12:01 · Yahoo
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026
2026-05-14 16:51 · Yahoo
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights
2026-05-11 21:21 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.